retatrutide parkinson's disease trial nct Frontiers Quarterly Drug Pipeline: October 2024

It has to shift priority from nonessential things to more essential things

The results of a meta-analysis indicate that GLP-1RAs can reduce major adverse cardiovascular events (MACE) such as cardiovascular death, stroke, or myocardial infarction, as well as hospital admissions for heart failure and all-cause mortality, in patients with T2D [44]

Chitosan microneedle patches for sustained transdermal delivery of macromolecules

Focus: Long-term health, metabolic optimization, comfortable maintenance

Engage in regular physical activity, such as brisk walking, cycling, or swimming

Among these breakthroughs, Tirzepatide has emerged as a promising and revolutionary medication